The development of novel mAbs with high specificity and efficacy against glycosylation variations, CD24 peptides, BiTEs, CAR-T, and/or CD24-CAR NK cells could be among the tactics used in CD24/Siglec-10-targeted cancer immunotherapy in the future. Here, CD24 is linked to cancer.